STOCK TITAN

Immuneering Corporation - IMRX STOCK NEWS

Welcome to our dedicated page for Immuneering Corporation news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering Corporation stock.

Immuneering Corporation (symbol: IMRX) is a biopharmaceutical company at the forefront of the fight against debilitating oncologic and neurologic diseases. Through the application of cutting-edge translational bioinformatics, Immuneering aims to improve patient outcomes and enhance the drug development process.

The company leverages its proprietary computational Disease Cancelling Technology platform to drive innovative drug discovery programs. This technology not only accelerates the identification of potential therapeutic candidates but also increases their success rates in clinical trials. Immuneering’s expertise extends beyond its own projects, offering unparalleled computational biology capabilities to various pharmaceutical and biotechnology companies.

Recent achievements include advancements in their key drug programs, IMM-1-104 and IMM-6-415, which are designed to target critical pathways involved in cancer and neurological disorders. The company’s financial condition remains robust, supported by strategic partnerships and continuous investment in research and development.

For the latest updates, Immuneering regularly communicates through media contacts such as Gina Nugent from Nugent Communications and investor contacts like Laurence Watts and Kiki Patel from Gilmartin Group. These channels ensure stakeholders are promptly informed about new developments, corporate highlights, and forward-looking statements.

Through its innovative approach and strategic collaborations, Immuneering Corporation stands as a significant player in the biopharmaceutical landscape, dedicated to transforming the treatment paradigms for some of the most challenging diseases.

Rhea-AI Summary
Immuneering Corporation (IMRX) to participate in Cowen 44th Annual Health Care Conference to discuss pipeline and business strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Immuneering Corporation (IMRX) reported financial results for Q4 and full year 2023, with topline data from Phase 1/2a trials expected in March 2024. FDA Fast Track designation received for IMM-1-104 in pancreatic cancer. Cash runway extended into 2H 2025. The company raised $30 million in an offering and reported positive Phase 1 data for IMM-1-104.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
Rhea-AI Summary
Immuneering Corporation (IMRX) receives Fast Track designation from the FDA for its lead clinical-stage program IMM-1-104 for pancreatic ductal adenocarcinoma. The company anticipates multiple readouts from its Phase 1/2a clinical trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
Rhea-AI Summary
Immuneering Corporation (IMRX) will participate in two February investor conferences to discuss the company’s pipeline, platform, and business strategy. The company aims to develop universal-RAS/RAF medicines for broad cancer patient populations. Participating will be the CEO, CSO, CBO, and CAO, discussing the company's progress and future plans. The conferences include Guggenheim 6th Annual Biotechnology Conference and Oppenheimer 34th Annual Healthcare Life Sciences Conference, with live webcasts available on Immuneering’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary
Immuneering Corporation (IMRX) has received FDA clearance for its Investigational New Drug (IND) application for IMM-6-415, paving the way for a Phase 1/2a clinical trial for the treatment of advanced RAF or RAS mutant solid tumors. The company expects to dose the first patient in early 2024. IMM-6-415 is a deep cyclic inhibitor of the MAPK pathway with unique drug-like properties and has shown promising preclinical single-agent and combination anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
-
Rhea-AI Summary
Immuneering Corporation (Nasdaq: IMRX) will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. The presentation will feature key executives and will be webcast live and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.45%
Tags
conferences
Rhea-AI Summary
IMRX: Immuneering Corporation Reports Progress on IMM-1-104 Phase 1/2a Trial, Expanded Clinical Development Plan, and Financial Results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Immuneering presents encouraging preclinical data for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
-
Rhea-AI Summary
Immuneering Corporation will present preclinical data on its lead clinical-stage program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data includes predicting activity of IMM-1-104 as a single agent and in combination for patients with RAS or RAF mutant tumors, as well as the anti-tumor activity and tolerability of IMM-6-415 in RAF mutant tumors. The abstracts will be available on the conference website and the posters will be available on Immuneering's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences clinical trial
Rhea-AI Summary
Immuneering Corporation to present at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences

FAQ

What is the current stock price of Immuneering Corporation (IMRX)?

The current stock price of Immuneering Corporation (IMRX) is $2 as of December 20, 2024.

What is the market cap of Immuneering Corporation (IMRX)?

The market cap of Immuneering Corporation (IMRX) is approximately 57.8M.

What does Immuneering Corporation do?

Immuneering Corporation focuses on improving patient outcomes for oncologic and neurologic diseases using advanced translational bioinformatics.

What is the Disease Cancelling Technology platform?

It is Immuneering’s proprietary computational platform that enhances drug discovery by identifying and targeting disease pathways.

What are some of Immuneering’s key drug programs?

IMM-1-104 and IMM-6-415 are prominent programs targeting cancer and neurological disorders.

How does Immuneering assist other pharmaceutical companies?

It provides unmatched computational biology capabilities to support drug discovery and development processes for other firms.

Who are the main contacts for media and investor relations at Immuneering?

Gina Nugent from Nugent Communications and Laurence Watts along with Kiki Patel from Gilmartin Group.

How can I stay updated on Immuneering’s latest news?

Follow Immuneering’s announcements through their media and investor relations contacts or visit their official website for updates.

What type of diseases is Immuneering focused on?

Immuneering targets oncologic (cancer-related) and neurologic (related to the nervous system) diseases.

What makes Immuneering’s approach unique in drug discovery?

Its use of computational Disease Cancelling Technology allows for more efficient and targeted drug discovery processes.

What recent milestones has Immuneering achieved?

Advancements in their drug programs, particularly IMM-1-104 and IMM-6-415, and maintaining a strong financial and developmental trajectory.

What strategic partnerships does Immuneering have?

Immuneering collaborates with various pharmaceutical and biotechnology companies to leverage its computational biology expertise.

Immuneering Corporation

Nasdaq:IMRX

IMRX Rankings

IMRX Stock Data

57.76M
22.40M
29.12%
30.11%
6.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE